GlassScriptPhysician profile
Micah Whitnell
NPI 1336845734
$1,998.90
in general payments reported to CMS, 2019-2025
35 companies · $673 in 2025
The $673 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $634 · 2024: $692 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,998.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $273.41 | 2024-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Abbvie INC. | $219.95 | 2023-2024 | |
| Eisai INC. | $151.24 | 2024-2025 | |
| Novo Nordisk INC | $134.58 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Biogen, INC. | $129.58 | 2024-2025 | Vumerity, Skyclarys |
| Takeda Pharmaceuticals U.S.A., INC. | $109.25 | 2023-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.11 | 2023-2024 | Tradjenta, Synjardy, Jardiance |
| Otsuka America Pharmaceutical, INC. | $68.09 | 2023-2025 | Rexulti |
| Lundbeck LLC | $61.23 | 2025 | Vyepti |
| Amgen INC. | $58.72 | 2023-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $51.08 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Sk Life Science, INC. | $49.35 | 2024-2025 | |
| Argenx US, INC. | $47.01 | 2025 | Vyvgart Hytrulo |
| Axsome Therapeutics, INC. | $46.74 | 2025 | Symbravo |
| Corium, LLC | $36.60 | 2023 | Azstarys |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micah Whitnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.